AARP and Leading Research Organizations Announced Risk Factors of Dementia Research Findings
On Nov. 15, 2024, the AARP, the Alzheimer’s Disease Data Initiative (AD Data Initiative), and the Institute for…
On Nov. 15, 2024, the AARP, the Alzheimer’s Disease Data Initiative (AD Data Initiative), and the Institute for…
On Apr. 1, 2024, Otsuka Pharmaceutica and Click Therapeutics announced that the U.S. Food and Drug Administration (FDA)…
On Dec. 14, 2023, Biogen and Sage Therapeutics announced ZURZUVAE (zuranolone) 50 mg (two 25 mg capsules per…
On Aug. 4, 2023, Biogen and Sage Therapeutics announced that the U.S. Food and Drug Administration (FDA) had…
On Mar. 8, 2023, Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted approval…
On May 19, 2022, the U.S. National Institutes of Health (NIH) announced that people who reported in a…
On Oct. 6, 2021, a study by researchers at the National Institutes of Health (NIH) found that episodes…
On Feb. 10, 2021, XPhyto announced it had added mescaline production to its psychedelic medicine programs. Further to…
On Oct. 27, 2020, a National Institutes of Health (NIH) study of 5,000 women found that approximately 1…
On May 27, 2020, the National Institutes of Health (NIH) announced it had found that molecules released into…
On Dec. 31, 2019, Ege T. Kavalali, Ph.D., professor and acting chair of the Department of Pharmacology in…
On Mar. 31, 2017, more than 300 million people are now living with depression, which is the leading…
On May 18, 2015, The Hersh Foundation annunced a $5 million lead gift to Southwestern Medical Foundation to…
On Aug. 24, 2004, Eli Lilly and Company launched Cymbalta (duloxetine HC), a new treatment for major depression…
On Apr. 19, 2004, Eli Lilly and Company launched Symbyax in the U.S., the first and only Food…
On Jun. 16, 2003, researchers at Stanford University Medical Center announced they found that a drug commonly prescribed…
On Dec. 16, 2002, researchers at Stanford University Medical Center announced they were continuing a multi-year clinical trial…